>
BREAKING: CBS 60 Minutes: revealed a previously unknown weapon that they believe is linked...
The Year of Adam Smith: Why the Savvy Scotsman Remains So Important
Trump sons trigger 'corruption' uproar as Pentagon drone venture surfaces amid Iran war
Will the Dollar be a Casualty of the Iran War?
The Pentagon is looking for the SpaceX of the ocean.
Major milestone by 3D printing an artificial cornea using a specialized "bioink"...
Scientists at Rice University have developed an exciting new two-dimensional carbon material...
Footage recorded by hashtag#Meta's AI smart glasses is sent to offshore contractors...
ELON MUSK: "With something like Neuralink… we effectively become maybe one with the AI."
DARPA Launches New Program Generative Optogenetics, GO,...
Anthropic Outpaces OpenAI Revenue 10X, Pentagon vs. Dario, Agents Rent Humans | #234
Ordering a Tiny House from China, what's the real COST?
New video may offer glimpse of secret F-47 fighter
Donut Lab's Solid-State Battery Charges Fast. But Experts Still Have Questions

A 13-year-old girl who was left completely bald from her alopecia has made an incredible transformation after taking an arthritis drug.
The unidentified teenager, from Brazil, had slowly been losing her hair for five years and standard medications failed to help. Doctors tried tofacitinib as a last-resort.
Tests of the drug, marketed as Xeljanz, have shown it can help alopecia patients regrow their hair – but it is not yet licensed as a conventional treatment.
After just four months, the girl regained a significant amount of her hair. She was left with thick, brown locks within two years of taking tofacitinib.
The results add to the evidence that the drug could offer hope for millions of patients around the world with alopecia, who have slim chances of making a full recovery.
Tofacitinib is routinely given to patient with rheumatoid arthritis, which is caused by inflammation. Dermatologists say the type of alopecia the girl had is caused by the same process.
Medical student Rachel Berbert Ferreira, at Centro Universitario Cesumar, was the senior author of the paper in Clinical Case Reports.